Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. Ferrara, R.; Mezquita, L.; Texier, M.; Lahmar, J.; Audigier-Valette, C.; Tessonnier, L.; Mazieres, J.; Zalcman, G.; Brosseau, S.; Le Moulec, S.; Leroy, L.; Duchemann, B.; Lefebvre, C.; Veillon, R.; Westeel, V.; Koscielny, S.; Champiat, S.; Ferte, C.; Planchard, D.; Remon, J.; Boucher, M. E.; Gazzah, A.; Adam, J.; Bria, E.; Tortora, G.; Soria, J. C.; Besse, B.; Caramella, C.. JAMA Oncol. 2018; 1543-1552: p.1543-1552. doi:10.1001/jamaoncol.2018.3676Article